TrialJournal of the European Academy of Dermatology and Venereology : JEADV2026

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results.

Andrzej Kaszuba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.